Ibezapolstat

DRUG2 trials

Sponsors

Acurx Pharmaceuticals Inc.

Conditions

Clostridium Difficile InfectionClostridium Difficile Infection Recurrence

Phase 2

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

CompletedNCT04247542

Acurx Pharmaceuticals Inc.Clostridium Difficile Infection

Start: 2020-03-06End: 2023-11-15Updated: 2025-01-17

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

RecruitingNCT07513285

Acurx Pharmaceuticals Inc.Clostridium Difficile Infection Recurrence

Start: 2026-08-06End: 2027-11-24Target: 20Updated: 2026-08-12

Related Papers

Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study.

2025-06-112 citations

P-1109. A phase 2, randomized, double-blind study of ibezapolstat compared with vancomycin for the treatment of <i>Clostridioides difficile</i> infection: clinical and microbiome evaluation

Open Forum Infectious Diseases2025-01-291 citations